<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367976</url>
  </required_header>
  <id_info>
    <org_study_id>2012L01494</org_study_id>
    <nct_id>NCT02367976</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety on Prouk for STEMI Patients in China</brief_title>
  <official_title>A Phase III Study to Research the Efficacy and Safety on Prouk for ST Elevated Mycadial Infarction Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou RxD Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou RxD Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of rh-prouk as
      pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed
      as a multicenter, active controlled, single blinded study. The primary endpoint is to assess
      the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to
      evaluate the mortality rate at day 30.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of rh-prouk as
      pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed
      as a multicenter, active controlled, single blinded study. The primary endpoint is to assess
      percentage of patients achieve the coronary recanalization 90 minutes after thrombolysis. The
      secondary endpoint is to evaluate the mortality rate at day 30.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the percentage of STEMI patients achieving the recanalization of Coronary between the two arms</measure>
    <time_frame>90 minutes after administrative of active/comparator</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>rhprouk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhprouk to be administrated in 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlled</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The controlled arm patients will be administrated in 90 minutes after randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhprouk</intervention_name>
    <description>rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed</description>
    <arm_group_label>rhprouk</arm_group_label>
    <other_name>Controlled</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chest pain &gt; 30 minutes, while &lt;12 hours

          -  Expected PCI related delayed time &gt; 60 minutes, OR Door To Balloon time &gt;90 minutes

          -  ECG confirmed STEMI.

          -  Age: 18--75 years old

          -  Weight &lt;=85Kg

          -  Consent to participate in this study

        Exclusion Criteria

          -  Evidence of cardiac rupture;

          -  ECG: new left bundle branch block;

          -  Thrombolysis contradictions

          -  Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or
             spinal surgery) or recent trauma to the head or cranium (i.e. &lt; 3 months);

          -  Active bleeding or known bleeding disorder.

          -  Recent administration of any i.v. or s.c. anticoagulation within 12 hours
             includingunfractionated heparin, enoxaparin and/or bivalirudin or current use of oral
             anticoagulation(warfarin or coumadin);

          -  Uncontrolled hypertension, defined as a single blood pressure measurement ≥ 180/110 mm
             Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation;

          -  Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2
             months (this includes any trauma associated with the current myocardial infarction);
             Prolonged or traumatic cardiopulmonary resuscitation (&gt; 10 minutes) within the past 2
             Weeks Major surgery pending in the following 30 days;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiqun Shen, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou RxD Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiqun Shen, MD/PhD</last_name>
    <email>jingzhang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Zhang, PhD</last_name>
    <email>jingzhang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenyang Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqun Shen, MD/PhD</last_name>
      <email>jingzhang@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Zhang, PhD</last_name>
      <email>jingzhang@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yaling Han, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geng Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

